\ Clinical Trials – Phase 1 KEYNOTE-200
ASX Linkedin Twitter               


Clinical Trials – Phase 1 KEYNOTE-200

KEYNOTE-200 Trial

Status: Recruiting patients

A Phase 1 trial entitled KEYNOTE-200 or STORM (Systemic Treatment Of Resistant Metastatic disease) currently underway. It is a two part study as follows:

  • VLA-009A conducted in the UK employs CAVATAK® intravenously as a monotherapy in patients with late stage solid tumors including Non-Small Cell Lung Cancer (NSCLC), Castrate-Resistant Prostate Cancer, Melanoma and Bladder Cancer.
  • VLA-009B / KEYNOTE-200 conducted in the US and UK, in collaboration with Merck, employs intravenous use of CAVATAK with pembrolizumab (Keytruda®) in patients with NSCLC and Bladder Cancer with the aim to evaluate the safety and efficacy of this novel immunotherapy combination.

For further information about this trial, please visit the Clinical Trial website at ClinicalTrials.gov Identifier: NCT02043665

Click here for the latest news on the KEYNOTE-200 study

Click here for the announcement of the collaboration with Merck for the second stage of the trial.

Viralytics Limited
Suite 305, Level 3, 66 Hunter Street
Sydney NSW 2000 Australia
T: +61 (0)2 9988 4000 F: +61 (0)2 8068 6038

© Viralytics Limited 2018
This information does not take your circumstances into account. Read the relevant ASX releases, financial reports and prospectuses before making an investment decision. Shares in Viralytics Limited, ABN 12 010 657 351, are traded on the Australian Stock Exchange (ASX:VLA) and on the over-the-counter market (OTC: VRACY).